annual
gener
meet
develop
countri
vaccin
manufactur
network
dcvmn
gather
vaccin
expert
membercompani
emerg
countri
nonmemb
compani
nonindustri
organ
inspir
innov
promot
global
access
vaccin
meet
host
sk
chemic
cohost
intern
vaccin
institut
ivi
seoul
south
korea
focus
pandem
epidem
partnership
dcvmn
presid
datla
open
meet
note
increas
global
uptak
vaccin
year
dcvmn
exist
j
ahn
welcom
attende
express
sk
chemic
commit
healthcar
resolut
tackl
press
publichealth
issu
innov
partnership
korean
deputi
minist
health
welfar
kwon
emphas
vaccin
part
social
secur
korea
describ
effort
expand
support
vaccin
berkley
report
immun
coverag
vaccin
increas
point
sinc
launch
gavi
support
poorest
countri
vaccin
suppli
base
grown
manufactur
countri
countri
role
dcvmn
manufactur
vaccin
suppli
illustr
figur
impact
increas
vaccin
coverag
substanti
still
million
newborn
annual
receiv
basic
vaccin
gavi
role
outbreak
prepared
respons
also
grow
maintain
stockpil
yellow
fever
measl
cholera
vaccin
invest
addit
key
vaccin
ebola
recent
project
support
introduct
eubiolog
new
oral
cholera
vaccin
gavi
countri
cernuschi
note
selfprocur
middleincom
countri
need
better
inform
avail
product
supplier
demand
suppli
forecast
price
inform
improv
decisionmak
manag
vaccin
shortag
vaccin
price
product
procur
platform
address
gap
collect
vaccin
price
data
countri
fig
initi
aim
inform
global
suppli
polici
strategi
also
involv
global
dialogu
facilit
humanitarian
mechan
launch
year
facilit
time
access
afford
vaccin
humanitarian
emerg
rautio
outlin
unicef
stockpil
strategi
prioriti
forecast
fund
contract
activ
unicef
procur
around
billion
dose
whoprequalifi
vaccin
distribut
around
countri
manag
demand
realloc
suppli
levelout
fluctuat
avert
crise
sinc
unicef
respond
around
humanitarian
situat
countri
annual
peak
fig
bival
oral
polioviru
vaccin
bopv
roll
buffer
million
dose
maintain
million
dose
bulk
maintain
manufactur
readi
deliveri
within
month
uniqu
challeng
present
opv
type
stockpil
establish
support
global
polio
erad
initi
gpei
type
outbreak
occur
follow
withdraw
trival
opv
appli
opv
type
secur
futur
bopv
cessat
r
rustan
provid
overview
biofarma
suppli
bopv
polio
vaccin
bulk
last
five
year
estim
suppli
routin
supplementari
immun
develop
sabin
ipv
progress
bulk
stockpil
monoval
opv
type
establish
collabor
gpei
lewi
unicef
review
expect
increas
inactiv
polio
vaccin
ipv
avail
offer
receiv
manufactur
ipv
tender
l
meng
mention
china
nation
biotechnolog
group
sabin
ipv
vaccin
licens
plan
produc
million
dose
end
meet
domest
market
need
also
pipelin
sabin
ipv
vaccin
wuhan
site
sinovac
minhai
biotechnolog
china
excess
ipv
capac
avail
intern
suppli
zipurski
updat
audienc
whopolio
endgam
wild
polioviru
continu
transmit
pakistan
afghanistan
six
vaccinederiv
polioviru
type
outbreak
record
syria
pakistan
nigeria
democrat
republ
congo
prioriti
manag
polio
next
six
month
surveil
halt
transmiss
contain
malham
describ
gavi
progress
three
strateg
prioriti
first
support
govern
evalu
vaccin
introduct
forecast
total
system
effect
sustain
initi
start
assist
countri
assess
futur
demand
understand
tradeoff
make
decis
deliveri
best
overal
valu
coverag
vari
set
second
support
innov
meet
programmat
need
improv
coverag
equiti
third
activ
build
industri
engag
publish
suppli
procur
roadmap
product
share
budgetlimit
strateg
demandforecast
e
torreel
report
san
msf
administ
million
vaccin
dose
countri
acknowledg
critic
role
dcvmn
manufactur
improv
afford
access
msf
contribut
overcom
intellectu
properti
registr
barrier
challeng
high
cost
vaccin
constitut
barrier
access
msf
also
involv
clinic
studi
collabor
dcvmn
manufactur
vaccin
thermost
clinic
trial
new
product
procur
financ
discuss
moder
sobti
rautio
comment
unicef
continu
support
countri
graduat
gavi
vaccin
procur
practition
exchang
forum
procur
servic
l
meng
describ
chines
central
procur
system
annual
usd
million
budget
enabl
public
privat
manufactur
particip
tender
bryant
elabor
procur
vaccin
yellow
fever
japanes
enceph
vaccin
emerg
outbreak
joint
extern
evalu
tool
avail
support
plan
oswald
recommend
balanc
afford
vaccin
viabl
manufactur
invest
largescal
innov
product
follow
object
separ
need
public
organ
accept
higher
price
ensur
sustain
varga
outlin
four
key
principl
paho
revolv
fund
pool
procur
made
immun
latin
america
success
sustain
local
vaccin
legisl
share
goal
solidar
financi
corespons
provis
result
vaccin
cost
support
nation
budget
latin
american
countri
r
hatchett
outlin
gap
late
preclin
develop
proofofconcept
studi
human
outbreak
vaccin
led
launch
coalit
epidem
prepared
innov
cepi
januari
cepi
aim
speed
outbreak
prepared
respons
ensur
market
predict
promot
equiti
access
vaccin
target
time
week
antigen
identif
clinic
trial
batch
avail
week
clinic
trial
start
demonstr
like
clinic
benefit
week
goahead
product
million
dose
initi
propos
middl
east
respiratori
syndrom
mer
lassa
nipah
viru
vaccin
undergo
evalu
briand
present
whostrategi
elimin
yellow
fever
epidem
eye
yellow
fever
reemerg
despit
avail
effect
vaccin
present
global
threat
forti
countri
target
billion
dose
vaccin
need
major
urban
outbreak
africa
south
america
diseas
spread
countri
popul
immun
must
increas
highrisk
endem
countri
success
use
fraction
dose
kinshasa
democrat
republ
congo
help
allevi
insuffici
suppli
j
kim
ivi
describ
mer
korean
outbreak
first
driven
humantohuman
transmiss
outsid
middl
east
one
infect
travel
result
quarantin
almost
peopl
confirm
case
death
mer
outbreak
mostli
saudi
arabia
global
risk
mer
increas
largescal
travel
migrat
case
case
fatal
rate
fig
mani
vaccin
candid
mostli
preclin
test
lack
correl
protect
anim
model
present
challeng
dna
candid
vaccin
complet
preclin
studi
approv
firstinhuman
trial
european
vaccin
initi
evi
productdevelop
partnership
repres
leroy
help
control
diseas
poverti
build
sustain
vaccin
pipelin
evi
ecfund
zikavax
project
partnership
institut
pasteur
themi
cea
fasttrack
develop
vaccin
candid
use
liveattenu
measl
vector
first
candid
phase
trial
discuss
epidem
pandem
prepared
moder
fried
leroy
highlight
global
leadership
dialogu
need
establish
coordin
strategi
harmon
regulatori
requir
precioso
describ
butantan
challeng
demonstr
efficaci
two
zika
vaccin
candid
absenc
diseas
transmiss
establish
test
agre
clinic
endpoint
human
challeng
studi
may
need
advanc
clinic
develop
zuma
biomanguinho
note
high
coverag
full
dose
routin
immun
yellow
fever
provid
best
protect
children
vaccin
use
fraction
dose
control
outbreak
desai
zyduscadila
discuss
need
build
comprehens
respons
congocrimea
hemorrhag
fever
includ
veterinari
human
vaccin
postexposur
treatment
r
hatchett
note
cepi
develop
agreement
compani
support
vaccin
manufactur
diseas
epidem
potenti
particularli
routin
market
vaccin
ibna
masud
outlin
technolog
transfer
incepta
bangladesh
ivi
cholera
vaccin
clinic
studi
progress
b
abelaridd
present
initi
control
neglect
tropic
diseas
multipl
partner
pledg
support
control
elimin
erad
priorit
diseas
rabi
elimin
present
next
major
opportun
prevent
death
annual
mostli
among
children
africa
south
east
aim
zero
human
death
rabi
manufactur
encourag
prequalifi
novel
rabi
product
support
initi
w
ampofo
spoke
novel
african
vaccin
manufactur
initi
avmi
africa
global
popul
high
popul
growth
highest
childhood
mortal
rate
repres
global
vaccin
market
vaccin
produc
african
facil
fulfil
african
vaccin
need
public
health
emerg
ebola
highlight
region
vulner
galvan
support
local
manufactur
avmi
form
advanc
vaccin
manufactur
africa
advocaci
resourc
mobil
capacitybuild
africawid
studi
manufactur
costdriv
procur
africa
publish
oswald
bgmf
note
vaccin
manufactur
rais
strateg
question
compet
balanc
valu
access
partnership
current
pipelin
mani
similar
vaccin
priorit
candid
challeng
integr
align
purpos
conscienti
build
relationship
trust
among
partner
imper
sustain
suppli
discuss
challeng
benefit
public
privat
sector
collabor
moder
g
rockman
makhoana
biovac
announc
productdevelop
partnership
group
b
streptococcu
gb
vaccin
respons
african
need
use
conjug
technolog
develop
bionet
gil
describ
sinergium
partnership
multin
compani
base
publicpriv
consortium
model
sinergium
provid
facil
multin
provid
product
relat
technolog
local
govern
commit
longterm
market
tender
success
influenza
pneumococc
late
hpv
vaccin
suppli
argentina
k
ella
bharat
biotech
describ
path
partnership
rotaviru
typhoid
chikungunya
vaccin
p
khouri
olog
bioservic
discuss
fillfinish
servic
satisfi
bulk
manufactur
small
manufactur
surg
capac
need
b
abela
support
partnership
sustain
access
rabi
vaccin
g
rockman
conclud
innov
complex
partnership
requir
share
experi
inform
transpar
decisionmak
e
cook
review
role
vaccin
registr
develop
countri
includ
gener
guidanc
document
emerg
use
assess
list
eual
pipelin
vaccin
guidanc
document
prepar
nucleic
acid
hepat
e
mening
b
enteroviru
vaccin
overcom
registr
delay
avoid
duplic
effort
advanc
access
vaccin
collabor
procedur
joint
dossier
review
committe
implement
bhaskaran
share
overview
bmgf
work
support
regulatori
approv
lifecycl
manag
vaccin
drug
key
strateg
principl
relianc
reengin
region
vision
effici
transpar
predict
regulatori
pathway
global
health
product
includ
move
quickli
manufactur
countri
prequalif
receiv
countri
adopt
new
product
n
dellepian
present
compar
studi
dossier
format
content
evalu
procedur
applic
form
vaccin
registr
differ
countri
applic
form
eight
countri
registr
procedur
import
countri
compar
reveal
diverg
requir
better
align
common
technic
document
ctd
number
content
standard
modelappl
form
converg
evalu
procedur
includ
relianc
prequalif
would
improv
registr
effici
b
akanmori
share
experi
build
regulatori
capac
african
vaccin
regulatori
forum
avaref
establish
african
countri
overcom
regulatori
challeng
clinic
trial
registr
postlicensur
surveil
expert
also
discuss
challeng
improv
epidem
regulatori
prepared
particularli
countri
ebola
zika
mer
outbreak
could
surfac
sohn
note
korea
member
countri
acceler
approv
exempt
gmp
onsit
inspect
agreement
mutual
recognit
b
akanmori
mention
joint
review
success
mechan
acceler
review
clinic
trial
registr
applic
africa
r
hatchett
agre
wellinform
regul
better
equip
anticip
need
evalu
countermeasur
solut
may
includ
human
challeng
trial
investig
product
stockpil
dat
vabiotech
ad
surrog
efficaci
endpoint
could
consid
approv
new
vaccin
despit
harmon
dossier
within
countri
redund
inspect
supplement
clinic
studi
still
delay
registr
h
iyer
note
outbreak
respons
time
critic
e
cook
conclud
commun
among
regul
key
creat
solut
outbreak
control
continu
consid
publish
evid
propos
improv
registr
vaccin
develop
countri
c
rodriguez
review
prequalif
process
programmat
suitabl
prequalif
pspq
vaccin
activ
follow
prequalif
vaccin
common
challeng
prequalif
includ
incomplet
dossier
lack
data
commerci
scale
cell
bank
character
lot
consist
inappropri
clinic
trial
compar
product
nonregistr
clinic
trial
defici
qualiti
system
differ
nation
regul
deviat
programmat
suitabl
criteria
commun
technic
assist
regulatori
strategi
place
reduc
also
describ
experi
facilit
access
new
ebola
vaccin
candid
outbreak
outcom
includ
expedit
review
clinic
trial
emerg
setup
preeual
process
databas
strengthen
decisionmak
capac
emerg
respons
surveil
system
improv
meek
discuss
transit
product
summari
file
psf
ctd
format
vaccin
prequalif
submiss
ctd
use
regulatori
agenc
increas
challeng
anticip
product
licens
countri
use
ctd
differ
ctd
format
meek
also
review
posit
guidanc
bar
code
control
temperatur
chain
ctc
refer
guidelin
programmat
suitabl
label
space
constraint
cost
implic
barcod
recogn
present
ctc
intend
campaign
strateg
vaccin
routin
use
stabil
must
proven
regardless
remain
shelflif
addit
clinic
data
need
provid
stabil
test
offer
suffici
assur
vaccin
meet
clinicallytest
qualiti
specif
zehrung
path
review
novel
primari
contain
packag
technolog
preform
plastic
vial
success
use
oral
rotaviru
cholera
vaccin
compact
prefil
autodispos
uniject
contain
use
biofarma
hepat
b
vaccin
apiject
rommelag
develop
blowfills
design
parenter
deliveri
multipl
singledos
packag
configur
maropack
multin
evalu
blowfills
technolog
date
use
nonheat
sensit
product
vaccin
packag
technolog
cartridg
develop
duojectpnuvax
applic
stevanato
group
glass
cartridg
ampoul
design
integr
reconstitut
administr
devic
test
deliveri
heatstabl
rotaviru
vaccin
path
cost
model
studi
confirm
innov
reduc
overal
cost
vaccin
deliveri
wast
dispos
kahn
provid
updat
ctc
specif
set
condit
allow
vaccin
storag
transport
outsid
tradit
cold
chain
specifi
time
period
appli
vaccin
toler
temperatur
least
least
day
refer
vaccin
toler
temperatur
specifi
time
suitabl
ctc
must
test
licens
prequalifi
key
tool
vaccin
vial
monitor
vvm
pointofus
peak
threshold
temperatur
indic
ctc
work
group
establish
rush
outlin
innov
temperatur
monitor
four
establish
vvm
categori
avail
vaccin
new
commerci
consid
novel
vvm
develop
ctc
use
combin
singl
indic
cumul
vvm
respons
temperatur
rapidrespons
peakthreshold
indic
hightemperatur
exposur
fig
temptim
also
develop
barcod
vvm
correspond
reader
ideal
use
cellphon
applic
improv
patient
safeti
address
intern
anticounterfeit
trackandtrac
serial
requir
u
kreysa
present
role
provid
global
crossindustri
standard
barcod
gener
prefer
product
profil
vaccin
recommend
barcod
standard
packag
level
use
manufactur
except
primari
packag
current
voluntari
regul
buyer
may
requir
packag
standard
complianc
futur
pilot
project
implement
develop
countri
describ
lewi
gave
updat
unicef
barcod
project
countri
manufactur
awar
ctc
promot
ctc
tenderevalu
criterion
addit
project
support
wast
carbon
footprint
reduct
safe
inject
equip
next
tender
round
requir
industri
report
greenmanufactur
implement
weight
volum
local
product
criteria
introduct
electron
tender
process
vaccin
arriv
report
applic
test
launch
global
kothari
present
optim
product
purif
typhoid
vi
polysaccharid
clinic
isol
india
upstream
improv
includ
use
fedbatch
cultur
optim
media
downstream
improv
optim
diafiltr
replac
precipit
step
chromatographi
result
higher
vi
recoveri
futur
effort
focu
reduc
product
impur
endotoxin
l
liu
institut
medic
biolog
chines
academi
medic
scienc
lundgren
ge
healthcar
present
enteroviru
vaccin
develop
human
diploid
cell
viru
like
particl
vlp
insect
cell
produc
wave
bioreactor
pass
flowthrough
chromatographi
two
bind
step
flowthrough
chromatographi
core
bead
contain
pore
soak
contamin
protein
small
dna
fragment
allow
viru
vlp
pass
wide
applic
core
bead
mani
vaccin
discuss
p
tippoo
describ
biovac
develop
path
novel
vaccin
gb
lead
caus
sepsi
mening
neonat
young
infant
found
high
proport
pregnant
women
pentaval
gb
conjug
vaccin
pregnant
women
base
purifi
capsular
polysaccharid
conjug
gb
serotyp
ia
ib
ii
iii
v
jadhav
serum
institut
india
report
first
thermost
lyophil
oral
rotaviru
vaccin
avail
india
liveattenu
bovinehuman
rotaviru
reassort
grown
vero
cell
includ
serotyp
lyophil
vaccin
stabl
temperatur
higher
month
three
dose
show
efficaci
sever
rotaviru
gastroenter
among
infant
niger
singledos
plastic
vial
present
expect
avail
end
fillseal
technolog
inactiv
oral
cholera
vaccin
ocv
describ
baik
eubiolog
facilit
easi
safe
administr
vaccin
follow
reformul
ocv
develop
vietnam
ivi
technolog
process
optim
eubiolog
clinic
studi
demonstr
noninferior
vaccin
approv
januari
prequalif
achiev
decemb
fillseal
present
valid
approv
prequalifi
august
present
reduc
packag
volum
ship
weight
improv
storag
transport
wast
manag
lee
taiwan
share
mdck
cellderiv
influenza
vaccin
develop
use
highrisk
pandem
strain
enhanc
surveil
asian
virus
human
poultri
recommend
human
case
death
report
mdck
cellbas
influenza
vaccin
candid
produc
medigen
underw
clinic
trial
taiwan
result
indic
inactiv
wholeviru
vaccin
immunogen
vlp
split
subunit
antigen
tomar
cadila
biolog
present
new
nanoparticl
technolog
platform
base
baculoviru
cell
express
recombin
properli
fold
function
antigen
platform
flexibl
manufactur
clinicalgrad
materi
month
thu
suitabl
pandem
outbreak
vaccin
use
produc
vlp
season
pandem
influenza
well
protein
micel
rabi
ebola
mer
zika
antigen
vlp
influenza
vaccin
licens
india
recombin
rabi
gprotein
nanoparticl
candid
phase
iii
clinic
trial
nahm
discuss
immunoassay
technolog
test
vaccin
streptococcu
pneumonia
common
nasopharyng
gramposit
bacterium
caus
pneumonia
otiti
media
mening
polysaccharid
vaccin
becam
avail
polysaccharid
conjug
vaccin
licens
base
immunogen
data
without
efficaci
studi
thu
reduc
cost
new
product
develop
immunogen
measur
quantit
elisa
opsonophagocytosi
assay
opa
measur
protect
function
opa
multiplex
allow
acceler
vaccin
develop
reduc
serum
requir
high
analyt
throughput
avail
robust
standard
procedur
close
lectur
fried
consid
novel
vaccin
improv
made
advanc
product
deliveri
administr
protect
level
durat
clear
valu
proposit
balanc
like
risk
reward
essenti
need
addit
innov
human
vaccin
birth
old
age
highlight
tabl
vaccin
older
adult
prevent
ill
result
agerel
declin
immun
system
function
well
consequ
antibiot
resist
furthermor
innov
solut
need
address
challeng
declin
vaccin
coverag
affect
countri
dr
fried
conclud
appreci
impact
vaccin
health
age
continu
innov
vaccin
industri
programm
expand
reach
complex
innov
creation
prevent
opportun
becom
relev
major
benefit
dcvmn
annual
meet
facilit
commun
emerg
countri
industri
global
health
organ
